Pharmacogenomics and epilepsy: the road ahead.

Hdl Handle:
http://hdl.handle.net/10147/230654
Title:
Pharmacogenomics and epilepsy: the road ahead.
Authors:
Cavalleri, Gianpiero L; McCormack, Mark; Alhusaini, Saud; Chaila, Elijah; Delanty, Norman
Affiliation:
Molecular & Cellular Therapeutics, the Royal College of Surgeons in Ireland, Dublin, Ireland. gcavalleri@rcsi.ie
Citation:
Pharmacogenomics and epilepsy: the road ahead. 2011, 12 (10):1429-47 Pharmacogenomics
Journal:
Pharmacogenomics
Issue Date:
Oct-2011
URI:
http://hdl.handle.net/10147/230654
DOI:
10.2217/pgs.11.85
PubMed ID:
22008048
Abstract:
Epilepsy is one of the most common, serious neurological disorders, affecting an estimated 50 million people worldwide. The condition is typically treated using antiepileptic drugs of which there are 16 in widespread use. However, there are many different syndrome and seizure types within epilepsy and information guiding clinicians on the most effective drug and dose for individual patients is lacking. Further, all of the antiepileptic drugs have associated adverse reactions, some of which are severe and life-threatening. Here, we review the pharmacogenomic work to date in the context of these issues and comment on key aspects of study design that are required to speed up the identification of clinically relevant genetic factors.
Item Type:
Article
Language:
en
MeSH:
Alleles; Anticonvulsants; Biomarkers, Pharmacological; Epilepsy; Genome-Wide Association Study; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide
ISSN:
1744-8042

Full metadata record

DC FieldValue Language
dc.contributor.authorCavalleri, Gianpiero Len_GB
dc.contributor.authorMcCormack, Marken_GB
dc.contributor.authorAlhusaini, Sauden_GB
dc.contributor.authorChaila, Elijahen_GB
dc.contributor.authorDelanty, Normanen_GB
dc.date.accessioned2012-06-25T16:06:23Z-
dc.date.available2012-06-25T16:06:23Z-
dc.date.issued2011-10-
dc.identifier.citationPharmacogenomics and epilepsy: the road ahead. 2011, 12 (10):1429-47 Pharmacogenomicsen_GB
dc.identifier.issn1744-8042-
dc.identifier.pmid22008048-
dc.identifier.doi10.2217/pgs.11.85-
dc.identifier.urihttp://hdl.handle.net/10147/230654-
dc.description.abstractEpilepsy is one of the most common, serious neurological disorders, affecting an estimated 50 million people worldwide. The condition is typically treated using antiepileptic drugs of which there are 16 in widespread use. However, there are many different syndrome and seizure types within epilepsy and information guiding clinicians on the most effective drug and dose for individual patients is lacking. Further, all of the antiepileptic drugs have associated adverse reactions, some of which are severe and life-threatening. Here, we review the pharmacogenomic work to date in the context of these issues and comment on key aspects of study design that are required to speed up the identification of clinically relevant genetic factors.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Pharmacogenomicsen_GB
dc.subject.meshAlleles-
dc.subject.meshAnticonvulsants-
dc.subject.meshBiomarkers, Pharmacological-
dc.subject.meshEpilepsy-
dc.subject.meshGenome-Wide Association Study-
dc.subject.meshHumans-
dc.subject.meshPharmacogenetics-
dc.subject.meshPolymorphism, Single Nucleotide-
dc.titlePharmacogenomics and epilepsy: the road ahead.en_GB
dc.typeArticleen
dc.contributor.departmentMolecular & Cellular Therapeutics, the Royal College of Surgeons in Ireland, Dublin, Ireland. gcavalleri@rcsi.ieen_GB
dc.identifier.journalPharmacogenomicsen_GB
dc.description.provinceLeinsteren

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.